UBS raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $46 from $45 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Positive Outlook for Ionis Pharmaceuticals Driven by Strong Q2 Results and Promising Pipeline Developments
- Ionis Pharmaceuticals Reports Strong Earnings and Growth
- Ionis Pharmaceuticals: Hold Rating Amid Strong Performance and Future Uncertainties
- Ionis Pharmaceuticals: Strong Q2 Performance and Promising Future Catalysts Justify Buy Rating
- Ionis Pharmaceuticals price target raised to $65 from $50 at H.C. Wainwright